|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Singal AG, Kanwal F and Llovet JM: Global
trends in hepatocellular carcinoma epidemiology: implications for
screening, prevention and therapy. Nat Rev Clin Oncol. 20:864–884.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and
Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim DY: Changing etiology and epidemiology
of hepatocellular carcinoma: Asia and worldwide. J Liver Cancer.
24:62–70. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fan W, Adebowale K, Váncza L, Li Y, Rabbi
MF, Kunimoto K, Chen D, Mozes G, Chiu DK, Li Y, et al: Matrix
viscoelasticity promotes liver cancer progression in the
pre-cirrhotic liver. Nature. 626:635–642. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang D, Tang Z, Huang H, Zhou G, Cui C,
Weng Y, Liu W, Kim S, Lee S, Perez-Neut M, et al: Metabolic
regulation of gene expression by histone lactylation. Nature.
574:575–580. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang H, Wang X, Wang W, Qu X, Song X,
Zhang Y, Zhong L, Yang DP, Dong X and Zhao Y: Injectable hydrogel
for postoperative synergistic photothermal-chemodynamic tumor and
anti-infection therapy. Biomaterials. 280:1212892022. View Article : Google Scholar
|
|
9
|
Chen J, He G, Cai D, Giovannetti E,
Inamura K, Liu S and Ma W: Lactic acid: a narrative review of a
promoter of the liver cancer microenvironment. J Gastrointest
Oncol. 15:1282–1296. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zaib S, Hayyat A, Ali N, Gul A, Naveed M
and Khan I: Role of mitochondrial membrane potential and lactate
dehydrogenase A in apoptosis. Anticancer Agents Med Chem.
22:2048–2062. 2022. View Article : Google Scholar
|
|
11
|
Wang D, Du G, Chen X, Wang J, Liu K, Zhao
H, Cheng C, He Y, Jing N, Xu P, et al: Zeb1-controlled metabolic
plasticity enables remodeling of chromatin accessibility in the
development of neuroendocrine prostate cancer. Cell Death Differ.
31:779–791. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu Y, Hao X, Ren Y, Xu Q, Liu X, Song S
and Wang Y: Research progress of abnormal lactate metabolism and
lactate modification in immunotherapy of hepatocellular carcinoma.
Front Oncol. 12:10634232023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pan L, Feng F, Wu J, Fan S, Han J, Wang S,
Yang L, Liu W, Wang C and Xu K: Demethylzeylasteral targets lactate
by inhibiting histone lactylation to suppress the tumorigenicity of
liver cancer stem cells. Pharmacol Res. 181:1062702022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xie Y, Hu H, Liu M, Zhou T, Cheng X, Huang
W and Cao L: The role and mechanism of histone lactylation in
health and diseases. Front Genet. 13:9492522022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cui H, Xie N, Banerjee S, Ge J, Jiang D,
Dey T, Matthews QL, Liu RM and Liu G: Lung myofibroblasts promote
macrophage profibrotic activity through lactate-induced histone
lactylation. Am J Respir Cell Mol Biol. 64:115–125. 2021.
View Article : Google Scholar
|
|
16
|
Xiong J, He J, Zhu J, Pan J, Liao W, Ye H,
Wang H, Song Y, Du Y, Cui B, et al: Lactylation-driven
METTL3-mediated RNA m(6)A modification promotes immunosuppression
of tumor-infiltrating myeloid cells. Mol Cell. 82:1660–1677.e10.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang K, Fan M, Wang X, Xu J, Wang Y, Tu F,
Gill PS, Ha T, Liu L, Williams DL and Li C: Lactate promotes
macrophage HMGB1 lactylation, acetylation, and exosomal release in
polymicrobial sepsis. Cell Death Differ. 29:133–146. 2022.
View Article : Google Scholar :
|
|
18
|
Mao Y, Zhang J, Zhou Q, He X, Zheng Z, Wei
Y, Zhou K, Lin Y, Yu H, Zhang H, et al: Hypoxia induces
mitochondrial protein lactylation to limit oxidative
phosphorylation. Cell Res. 34:13–30. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ju J, Zhang H, Lin M, Yan Z, An L, Cao Z,
Geng D, Yue J, Tang Y, Tian L, et al: The alanyl-tRNA synthetase
AARS1 moonlights as a lactyltransferase to promote YAP signaling in
gastric cancer. J Clin Invest. 134:e1745872024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zong Z, Xie F, Wang S, Wu X, Zhang Z, Yang
B and Zhou F: Alanyl-tRNA synthetase, AARS1, is a lactate sensor
and lactyltransferase that lactylates p53 and contributes to
tumorigenesis. Cell. 187:2375–2392.e33. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li H, Liu C, Li R, Zhou L, Ran Y, Yang Q,
Huang H, Lu H, Song H, Yang B, et al: AARS1 and AARS2 sense
l-lactate to regulate cGAS as global lysine lactyltransferases.
Nature. 634:1229–1237. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Niu Z, Chen C, Wang S, Lu C, Wu Z, Wang A,
Mo J, Zhang J, Han Y, Yuan Y, et al: HBO1 catalyzes lysine
lactylation and mediates histone H3K9la to regulate gene
transcription. Nat Commun. 15:35612024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fan Z, Liu Z, Zhang N, Wei W, Cheng K, Sun
H and Hao Q: Identification of SIRT3 as an eraser of H4K16la.
iScience. 26:1077572023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moreno-Yruela C, Zhang D, Wei W, Bæk M,
Liu W, Gao J, Danková D, Nielsen AL, Bolding JE, Yang L, et al:
Class I histone deacetylases (HDAC1-3) are histone lysine
delactylases. Sci Adv. 8:eabi66962022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dai SK, Liu PP, Li X, Jiao LF, Teng ZQ and
Liu CM: Dynamic profiling and functional interpretation of histone
lysine crotonylation and lactylation during neural development.
Development. 149:dev2000492022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Moreno-Yruela C, Bæk M, Monda F and Olsen
CA: Chiral post-translational modification to Lysine ε-Amino
Groups. Acc Chem Res. 55:1456–1466. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zessin M, Meleshin M, Praetorius L, Sippl
W, Bařinka C and Schutkowski M: Uncovering robust delactoylase and
depyruvoylase activities of HDAC isoforms. ACS Chem Biol.
17:1364–1375. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
DeBerardinis RJ, Lum JJ, Hatzivassiliou G
and Thompson CB: The biology of cancer: Metabolic reprogramming
fuels cell growth and proliferation. Cell Metab. 7:11–20. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yao S, Xu MD, Wang Y, Zhao ST, Wang J,
Chen GF, Chen WB, Liu J, Huang GB, Sun WJ, et al: Astrocytic
lactate dehydrogenase A regulates neuronal excitability and
depressive-like behaviors through lactate homeostasis in mice. Nat
Commun. 14:7292023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Comandatore A, Franczak M, Smolenski RT,
Morelli L, Peters GJ and Giovannetti E: Lactate Dehydrogenase and
its clinical significance in pancreatic and thoracic cancers. Semin
Cancer Biol. 86(Pt): 93–100. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vayakkattil AB, Pazhanchery AS, Andrews S
and Vayakkattil U: The warburg effect redefined: A kinetic and
regulatory perspective. Cureus. 17:e933312025.PubMed/NCBI
|
|
32
|
Nagini S, Kallamadi PR, Tanagala KKK and
Reddy GB: Aldo-keto reductases: Role in cancer development and
theranostics. Oncol Res. 32:1287–1308. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Khayami R, Hashemi SR and Kerachian MA:
Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the
cancer process and its therapeutic potential. J Cell Mol Med.
24:8890–8902. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang T, Ye Z, Li Z, Jing DS, Fan GX, Liu
MQ, Zhuo QF, Ji SR, Yu XJ, Xu XW and Qin Y: Lactate-induced protein
lactylation: A bridge between epigenetics and metabolic
reprogramming in cancer. Cell Prolif. 56:e134782023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hu X, Huang X, Yang Y, Sun Y, Zhao Y,
Zhang Z, Qiu D, Wu Y, Wu G and Lei L: Dux activates
metabolism-lactylation-MET network during early iPSC reprogramming
with Brg1 as the histone lactylation reader. Nucleic Acids Res.
52:5529–5548. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhai G, Niu Z, Jiang Z, Zhao F, Wang S,
Chen C, Zheng W, Wang A, Zang Y, Han Y and Zhang K: DPF2 reads
histone lactylation to drive transcription and tumorigenesis. Proc
Natl Acad Sci USA. 121:e24214961212024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nunez R, Sidlowski PFW, Steen EA,
Wynia-Smith SL, Sprague DJ, Keyes RF and Smith BC: The TRIM33
bromodomain recognizes histone lysine lactylation. ACS Chem Biol.
19:2418–2428. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ogryzko VV, Schiltz RL, Russanova V,
Howard BH and Nakatani Y: The transcriptional coactivators p300 and
CBP are histone acetyltransferases. Cell. 87:953–959. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Narita T, Ito S, Higashijima Y, Chu WK,
Neumann K, Walter J, Satpathy S, Liebner T, Hamilton WB, Maskey E,
et al: Enhancers are activated by p300/CBP activity-dependent PIC
assembly, RNAPII recruitment, and pause release. Mol Cell.
81:2166–2182.e6. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen Q, Yang B, Liu X, Zhang XD, Zhang L
and Liu T: Histone acetyltransferases CBP/p300 in tumorigenesis and
CBP/p300 inhibitors as promising novel anticancer agents.
Theranostics. 12:4935–4948. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li F, Si W, Xia L, Yin D, Wei T, Tao M,
Cui X, Yang J, Hong T and Wei R: Positive feedback regulation
between glycolysis and histone lactylation drives oncogenesis in
pancreatic ductal adenocarcinoma. Mol Cancer. 23:902024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang X, Fan W, Li N, Ma Y, Yao M, Wang G,
He S, Li W, Tan J, Lu Q and Hou S: YY1 lactylation in microglia
promotes angiogenesis through transcription activation-mediated
upregulation of FGF2. Genome Biol. 24:872023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li L, Jiang D, Liu H, Guo C, Zhao R, Zhang
Q, Xu C, Qin Z, Feng J, Liu Y, et al: Comprehensive proteogenomic
characterization of early duodenal cancer reveals the
carcinogenesis tracks of different subtypes. Nat Commun.
14:17512023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen Z, Mei K, Xiao Y, Xiong Y, Long W,
Wang Q, Zhong J, Di D, Ge Y, Luo Y, et al: Prognostic assessment of
oxidative stress-related genes in colorectal cancer and new
insights into tumor immunity. Oxid Med Cell Longev.
2022:25183402022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu L, Gao J, Liu X, Zhang F, Hu B, Zhang
H, Wang Z, Tang H, Shi JH and Zhang S: AARS2 as a novel biomarker
for prognosis and its molecular characterization in pan-cancer.
Cancer Med. 12:21531–21544. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhu Z, Hou Q, Wang B, Li C, Liu L, Gong W,
Chai J and Guo H: A novel mitochondria-related gene signature for
controlling colon cancer cell mitochondrial respiration and
proliferation. Hum Cell. 35:1126–1139. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ishihama K, Yamakawa M, Semba S, Takeda H,
Kawata S, Kimura S and Kimura W: Expression of HDAC1 and CBP/p300
in human colorectal carcinomas. J Clin Pathol. 60:1205–1210. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Eichner LJ, Curtis SD, Brun SN, McGuire
CK, Gushterova I, Baumgart JT, Trefts E, Ross DS, Rymoff TJ and
Shaw RJ: HDAC3 is critical in tumor development and therapeutic
resistance in Kras-mutant non-small cell lung cancer. Sci Adv.
9:eadd32432023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang H, Fu C, Du J, Wang H, He R, Yin X,
Li H, Li X, Wang H, Li K, et al: Enhanced histone H3 acetylation of
the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for
PD-L1 expression in drug-resistant cancer cells. J Exp Clin Cancer
Res. 39:292020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jin J, Bai L, Wang D, Ding W, Cao Z, Yan
P, Li Y, Xi L, Wang Y, Zheng X, et al: SIRT3-dependent
delactylation of cyclin E2 prevents hepatocellular carcinoma
growth. EMBO Rep. 24:e560522023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zu H, Li C, Dai C, Pan Y, Ding C, Sun H,
Zhang X, Yao X, Zang J and Mo X: SIRT2 functions as a histone
delactylase and inhibits the proliferation and migration of
neuroblastoma cells. Cell Discov. 8:542022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jena BC, Das CK, Banerjee I, Bharadwaj D,
Majumder R, Das S, Biswas A, Kundu M, Roy PK, Kundu CN and Mandal
M: TGF-β1 induced autophagy in cancer associated fibroblasts during
hypoxia contributes EMT and glycolysis via MCT4 upregulation. Exp
Cell Res. 417:1131952022. View Article : Google Scholar
|
|
53
|
Hu X, Huang Z and Li L: LDHB mediates
histone lactylation to activate PD-L1 and promote ovarian cancer
immune escape. Cancer Invest. 43:70–79. 2025. View Article : Google Scholar
|
|
54
|
Huang Y, Zhang W, Hao J and Zhu R: The
application value of lactate dehydrogenase in gynecological
malignant tumors. Front Oncol. 15:17311872026. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Jha MK, Lee IK and Suk K: Metabolic
reprogramming by the pyruvate dehydrogenase kinase-lactic acid
axis: Linking metabolism and diverse neuropathophysiologies.
Neurosci Biobehav Rev. 68:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Bennis Y, Bodeau S, Batteux B,
Gras-Champel V, Masmoudi K, Maizel J, De Broe ME, Lalau JD and
Lemaire-Hurtel AS: A study of associations between plasma metformin
concentration, lactic acidosis, and mortality in an emergency
hospitalization context. Crit Care Med. 48:e1194–e1202. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Arce-Molina R, Cortés-Molina F, Sandoval
PY, Galaz A, Alegría K, Schirmeier S, Barros LF and San Martín A: A
highly responsive pyruvate sensor reveals pathway-regulatory role
of the mitochondrial pyruvate carrier MPC. Elife. 9:e539172020.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Schwab A, Siddiqui MA, Ramesh V,
Gollavilli PN, Turtos AM, Møller SS, Pinna L, Havelund JF, Rømer
AMA, Ersan PG, et al: Polyol pathway-generated fructose is
indispensable for growth and survival of non-small cell lung
cancer. Cell Death Differ. 32:587–597. 2025. View Article : Google Scholar :
|
|
59
|
Liu Y, Zhou C, Tang Y, Lei H, Aihemaiti A,
Liu H, Zou P, Xie J, Guo X, Xia R, et al: Targeting AKR1B1
reprograms tumor-associated macrophages to enhance antitumor
immunity. J Immunother Cancer. 14:e0140432026. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Liu Z, Yuan J, Su S, Han J, Zeng N, Ma Y,
Chen N and Lv T: AARS1-mediated AKR1B10 lactylation stabilizes an
aerobic glycolysis-positive feedback loop to drive lenvatinib
resistance in hepatocellular carcinoma. Clin Transl Med.
16:e705612026. View Article : Google Scholar
|
|
61
|
Miranda-Gonçalves V, Gonçalves CS, Granja
S, Vieira de Castro J, Reis RM, Costa BM and Baltazar F: MCT1 is a
new prognostic biomarker and its therapeutic inhibition boosts
response to temozolomide in human glioblastoma. Cancers (Basel).
13:34682021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Payen VL, Mina E, Van Hée VF, Porporato PE
and Sonveaux P: Monocarboxylate transporters in cancer. Mol Metab.
33:48–66. 2020. View Article : Google Scholar :
|
|
63
|
Singh M, Afonso J, Sharma D, Gupta R and
Kumar V, Rani R, Baltazar F and Kumar V: Targeting monocarboxylate
transporters (MCTs) in cancer: How close are we to the clinics?
Semin Cancer Biol. 90:1–14. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Clem B, Telang S, Clem A, Yalcin A, Meier
J, Simmons A, Rasku MA, Arumugam S, Dean WL, Eaton J, et al:
Small-molecule inhibition of 6-phosphofructo-2-kinase activity
suppresses glycolytic flux and tumor growth. Mol Cancer Ther.
7:110–120. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Feng Y, Xiong Y, Qiao T, Li X, Jia L and
Han Y: Lactate dehydrogenase A: A key player in carcinogenesis and
potential target in cancer therapy. Cancer Med. 7:6124–6136. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Basheeruddin M and Qausain S:
Hypoxia-inducible factor 1-Alpha (HIF-1α): An essential regulator
in cellular metabolic control. Cureus. 16:e638522024.
|
|
67
|
Gordan JD, Thompson CB and Simon MC: HIF
and c-Myc: sibling rivals for control of cancer cell metabolism and
proliferation. Cancer Cell. 12:108–113. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Dang CV, Hamaker M, Sun P, Le A and Gao P:
Therapeutic targeting of cancer cell metabolism. J Mol Med (Berl).
89:205–212. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Mossmann D, Park S and Hall MN: mTOR
signalling and cellular metabolism are mutual determinants in
cancer. Nat Rev Cancer. 18:744–757. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Allen E, Miéville P, Warren CM, Saghafinia
S, Li L, Peng MW and Hanahan D: Metabolic symbiosis enables
adaptive resistance to anti-angiogenic therapy that is dependent on
mTOR signaling. Cell Rep. 15:1144–1160. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Liao J, Chen Z, Chang R, Yuan T, Li G, Zhu
C, Wen J, Wei Y, Huang Z, Ding Z, et al: CENPA functions as a
transcriptional regulator to promote hepatocellular carcinoma
progression via cooperating with YY1. Int J Biol Sci. 19:5218–5232.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Xu H, Li L, Wang S, Wang Z, Qu L, Wang C
and Xu K: Royal jelly acid suppresses hepatocellular carcinoma
tumorigenicity by inhibiting H3 histone lactylation at H3K9la and
H3K14la sites. Phytomedicine. 118:1549402023. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Yang Z, Yan C, Ma J, Peng P, Ren X, Cai S,
Shen X, Wu Y, Zhang S, Wang X, et al: Lactylome analysis suggests
lactylation-dependent mechanisms of metabolic adaptation in
hepatocellular carcinoma. Nat Metab. 5:61–79. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Wu X: In-depth discovery of protein
lactylation in hepatocellular carcinoma. Proteomics.
23:e23000032023. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Huang J, Xie H, Li J, Huang X, Cai Y, Yang
R, Yang D, Bao W, Zhou Y, Li T and Lu Q: Histone lactylation drives
liver cancer metastasis by facilitating NSF1-mediated ferroptosis
resistance after microwave ablation. Redox Biol. 81:1035532025.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Harmon C, Robinson MW, Hand F, Almuaili D,
Mentor K, Houlihan DD, Hoti E, Lynch L, Geoghegan J and O'Farrelly
C: Lactate-mediated acidification of tumor microenvironment induces
apoptosis of liver-resident NK cells in colorectal liver
metastasis. Cancer Immunol Res. 7:335–346. 2019. View Article : Google Scholar
|
|
77
|
Cheng S, Xiao X, Wang D, Wang X and Yang
M: Lactate and lactylation in liver diseases: Energy metabolism,
inflammatory immunity and tumor microenvironment. Front Immunol.
16:15815822025. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Shangguan X, He J, Ma Z, Zhang W, Ji Y,
Shen K, Yue Z, Li W, Xin Z, Zheng Q, et al: SUMOylation controls
the binding of hexokinase 2 to mitochondria and protects against
prostate cancer tumorigenesis. Nat Commun. 12:18122021. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Tan Q, Liu M and Tao X: Targeting
lactylation: From metabolic reprogramming to precision therapeutics
in liver diseases. Biomolecules. 15:11782025. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Gao R, Li Y, Xu Z, Zhang F, Xu J, Hu Y,
Yin J, Yang K, Sun L, Wang Q, et al: Mitochondrial pyruvate carrier
1 regulates fatty acid synthase lactylation and mediates treatment
of nonalcoholic fatty liver disease. Hepatology. 78:1800–1815.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Meng J, Yan C and Liu J: LDHA-mediated
histone lactylation promotes the nonalcoholic fatty liver disease
progression through targeting The METTL3/YTHDF1/SCD1 m6A axis.
Physiol Res. 73:985–999. 2024. View Article : Google Scholar
|
|
82
|
Jiang X, Stockwell BR and Conrad M:
Ferroptosis: Mechanisms, biology and role in disease. Nat Rev Mol
Cell Biol. 22:266–282. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Ji Y, Xu Z, Tang L, Huang T, Mu X, Ni C,
Tang B, Lu H, Zhang C, Yang S and Wang X: O-GlcNAcylation of YBX1
drives a glycolysis-histone lactylation feedback loop in
hepatocellular carcinoma. Cancer Lett. 631:2179572025. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Feng F, Wu J, Chi Q, Wang S, Liu W, Yang
L, Song G, Pan L, Xu K and Wang C: Lactylome analysis unveils
lactylation-dependent mechanisms of stemness remodeling in the
liver cancer stem cells. Adv Sci (Weinh). 11:e24059752024.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ma F and Yu W: The roles of lactate and
lactylation in diseases related to mitochondrial dysfunction. Int J
Mol Sci. 26:71492025. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Liu X, Wang J, Lao M, Liu F, Zhu H, Man K
and Zhang J: Study on the effect of protein lysine lactylation
modification in macrophages on inhibiting periodontitis in rats. J
Periodontol. 95:50–63. 2024. View Article : Google Scholar
|
|
87
|
Wei X, Zou L, Huang Y, Qiu C, Cheng G,
Chen Y and Rao J: LDHA-mediated YAP lactylation promotes the tumor
progression of hepatocellular carcinoma by inducing YAP
dephosphorylation and activation. Biol Direct. 20:642025.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Wang L, Zeng T, Wang Y, Wang G, Yu W,
Zhang J, Shi Y, Li J and Ding J: K90 lactylation orchestrates YAP
nuclear sequestration by impairing binding with exportin CRM1 and
enhances HCC malignancy. Cancer Lett. 611:2173862024. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Hong H, Han H, Wang L, Cao W, Hu M, Li J,
Wang J, Yang Y, Xu X, Li G, et al: ABCF1-K430-Lactylation promotes
HCC malignant progression via transcriptional activation of HIF1
signaling pathway. Cell Death Differ. 32:613–631. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Lu Y, Zhu J, Zhang Y, Li W, Xiong Y, Fan
Y, Wu Y, Zhao J, Shang C, Liang H and Zhang W: Lactylation-Driven
IGF2BP3-Mediated serine metabolism reprogramming and RNA
m6A-modification promotes lenvatinib resistance in HCC. Adv Sci
(Weinh). 11:e24013992024. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Han H, Wang S, Ma L, Yin H, Cheng X, Wang
Y, Xia S, Zhang Y, Zhang Y, Zhu R, et al: ASH2L-K312-Lac stimulates
angiogenesis in tumors to expedite the malignant progression of
hepatocellular carcinoma. Adv Sci (Weinh). 12:e094772025.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Jiang C, He X, Chen X, Huang J, Liu Y,
Zhang J, Chen H, Sui X, Lv X, Zhao X, et al: Lactate accumulation
drives hepatocellular carcinoma metastasis through facilitating
tumor-derived exosome biogenesis by Rab7A lactylation. Cancer Lett.
627:2176362025. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Sun Y, Luo C, Yang H, Ye J, Song F, Yi Q,
Zou W, Huang Y, Fan X, Wang L, et al: Lactylation Converts ABHD6
into a mitochondrial regulator that drives lenvatinib resistance in
hepatocellular carcinoma. Cancer Res. Mar 20–2026.Epub ahead of
print.
|
|
94
|
Li Q, Yu K, Zhou S, Fang C, Zhang L, Jin
F, Hou X, Yao F, Tang Y, Xu J, et al: JOSD1 drives hepatocellular
carcinoma malignancy by modulating the ubiquitination-lactylation
switch on PGAM1. Gut. Apr 28–2026.Epub ahead of print. View Article : Google Scholar
|
|
95
|
Liu S, Pan Y, Liu W, Bu X, Shao R, Wang Q,
Wu J, Wu C, Hu W, Xu J, et al: Lactylation-driven MVP upregulation
boosts immunotherapy resistance by inhibiting PD-L1 degradation in
hepatocellular carcinoma. J Immunother Cancer. 13:e0122302025.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Chen S, Zhao L, Han P, Liu J, Hou J, Liu
X, Zhao Q, Wang R, Wang F and Li J: Lactate drives immune
resistance via a pharmaceutically reversible
H3K18la-KIF20A-c-Myc-PD-L1 axis in hepatocellular carcinoma. Cancer
Biol Med. Apr 2–2026.Epub ahead of print. View Article : Google Scholar
|
|
97
|
Ye J, Gao X, Huang X, Huang S, Zeng D, Luo
W, Zeng C, Lu C, Lu L, Huang H, et al: Integrating single-cell and
spatial transcriptomics to uncover and elucidate GP73-Mediated
pro-angiogenic regulatory networks in hepatocellular carcinoma.
Research (Wash DC). 7:03872024.
|
|
98
|
Wei E, Ji D, Jia Y, Sun Z, Gao C, Zeng C,
Wang C, Yu M, Shang G, Xie L, et al: BRD9 recognizes
lactate-induced H3K18 lactylation to drive oncogenic chromatin
remodeling in hepatocellular carcinoma. Cell Death Differ. Mar
7–2026.Epub ahead of print. View Article : Google Scholar
|
|
99
|
Cai J, Zhang P, Cai Y, Zhu G, Chen S, Song
L, Du J, Wang B, Dai W, Zhou J, et al: Lactylation-Driven NUPR1
promotes immunosuppression of tumor-infiltrating macrophages in
hepatocellular carcinoma. Adv Sci (Weinh). 12:e24130952025.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Cai J, Song L, Zhang F, Wu S, Zhu G, Zhang
P, Chen S, Du J, Wang B, Cai Y, et al: Targeting SRSF10 might
inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy
in hepatocellular carcinoma. Cancer Commun (Lond). 44:1231–1260.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Zou X, Wang N, Guan C, Gao J, Shi W, Yang
C, Bi S, Zhang T and Zhong X: PRC1 promotes MAFLD progression by
regulating glycolysis/lactylation axis and forming a positive
feedback loop. J Nutr Biochem. 154:1103782026. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Xie J, Pan X and Xia Y: PDP1 drives
hepatocellular carcinoma progression by regulating senescence
through the cAMP/Ca(2+) signaling pathway. Biochem Pharmacol.
247:1177722026. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Sangro B, Sarobe P, Hervás-Stubbs S and
Melero I: Advances in immunotherapy for hepatocellular carcinoma.
Nat Rev Gastroenterol Hepatol. 18:525–543. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Hanahan D: Hallmarks of cancer: New
dimensions. Cancer Discov. 12:31–46. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Kasagi S, Zhang P, Che L, Abbatiello B,
Maruyama T, Nakatsukasa H, Zanvit P, Jin W, Konkel JE and Chen W:
In vivo-generated antigen-specific regulatory T cells treat
autoimmunity without compromising antibacterial immune response.
Sci Transl Med. 6:241ra782014. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Watson MJ, Vignali PDA, Mullett SJ,
Overacre-Delgoffe AE, Peralta RM, Grebinoski S, Menk AV,
Rittenhouse NL, DePeaux K, Whetstone RD, et al: Metabolic support
of tumour-infiltrating regulatory T cells by lactic acid. Nature.
591:645–651. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Watson M, Vignali P, Mullet S,
Overacre-Delgoffe A, Peralta R, Grebinoski S, Menk A, Rittenhouse
N, DePeaux K, Whetstone R, et al: 517 Regulatory T cell functional
identity is sustained by a glucose:lactate axis that is exploited
in the tumor microenvironment. J ImmunoTher Cancer. 8:A337–A655.
2020.
|
|
108
|
Gu J, Zhou J, Chen Q, Xu X, Gao J, Li X,
Shao Q, Zhou B, Zhou H, Wei S, et al: Tumor metabolite lactate
promotes tumorigenesis by modulating MOESIN lactylation and
enhancing TGF-beta signaling in regulatory T cells. Cell Rep.
39:1109862022. View Article : Google Scholar
|
|
109
|
Xue Q, Peng W, Zhang S, Wei X, Ye L, Wang
Z, Xiang X, Liu Y, Wang H and Zhou Q: Lactylation-driven TNFR2
expression in regulatory T cells promotes the progression of
malignant pleural effusion. J Immunother Cancer. 12:e0100402024.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Lopez Krol A, Nehring HP, Krause FF, Wempe
A, Raifer H, Nist A, Stiewe T, Bertrams W, Schmeck B, Luu M, et al:
Lactate induces metabolic and epigenetic reprogramming of
pro-inflammatory Th17 cells. EMBO Rep. 23:e546852022. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Han X and Jin R: Rewiring tumor-associated
macrophages in hepatocellular carcinoma. Front Immunol.
17:17756032026. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Mills CD, Kincaid K, Alt JM, Heilman MJ
and Hill AM: M-1/M-2 macrophages and the Th1/Th2 paradigm. J
Immunol. 164:6166–6173. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Huang Y, Ge W, Zhou J, Gao B, Qian X and
Wang W: The role of tumor associated macrophages in hepatocellular
carcinoma. J Cancer. 12:1284–1294. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Liu YT, Mao ZW, Ding Y and Wang WL:
Macrophages as targets in hepatocellular carcinoma therapy. Mol
Cancer Ther. 23:780–790. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Xu B, Liu Y, Li N and Geng Q: Lactate and
lactylation in macrophage metabolic reprogramming: Current progress
and outstanding issues. Front Immunol. 15:13957862024. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Noe JT, Rendon BE, Geller AE, Conroy LR,
Morrissey SM, Young LEA, Bruntz RC, Kim EJ, Wise-Mitchell A,
Barbosa de Souza Rizzo M, et al: Lactate supports a
metabolic-epigenetic link in macrophage polarization. Sci Adv.
7:eabi86022021. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Mendler AN, Hu B, Prinz PU, Kreutz M,
Gottfried E and Noessner E: Tumor lactic acidosis suppresses CTL
function by inhibition of p38 and JNK/c-Jun activation. Int J
Cancer. 131:633–640. 2012. View Article : Google Scholar
|
|
118
|
Brand A, Singer K, Koehl GE, Kolitzus M,
Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, et
al: LDHA-Associated lactic acid production blunts tumor
immunosurveillance by T and NK cells. Cell Metab. 24:657–671. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Husain Z, Huang Y, Seth P and Sukhatme VP:
Tumor-derived lactate modifies antitumor immune response: Effect on
myeloid-derived suppressor cells and NK cells. J Immunol.
191:1486–1495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Xie D, Zhu S and Bai L: Lactic acid in
tumor microenvironments causes dysfunction of NKT cells by
interfering with mTOR signaling. Sci China Life Sci. 59:1290–1296.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Plebanek MP, Xue Y, Nguyen YV, DeVito NC,
Wang X, Holtzhausen A, Beasley GM, Theivanthiran B and Hanks BA: A
lactate-SREBP2 signaling axis drives tolerogenic dendritic cell
maturation and promotes cancer progression. Sci Immunol.
9:eadi41912024. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Gottfried E, Kunz-Schughart LA, Ebner S,
Mueller-Klieser W, Hoves S, Andreesen R, Mackensen A and Kreutz M:
Tumor-derived lactic acid modulates dendritic cell activation and
antigen expression. Blood. 107:2013–2021. 2006. View Article : Google Scholar
|
|
123
|
Raychaudhuri D, Bhattacharya R, Sinha BP,
Liu CSC, Ghosh AR, Rahaman O, Bandopadhyay P, Sarif J, D'Rozario R,
Paul S, et al: Lactate induces pro-tumor reprogramming in
intratumoral plasmacytoid dendritic cells. Front Immunol.
10:18782019. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Dong H and Bullock TN: Metabolic
influences that regulate dendritic cell function in tumors. Front
Immunol. 5:242014. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Sonveaux P, Copetti T, De Saedeleer CJ,
Végran F, Verrax J, Kennedy KM, Moon EJ, Dhup S, Danhier P, Frérart
F, et al: Targeting the lactate transporter MCT1 in endothelial
cells inhibits lactate-induced HIF-1 activation and tumor
angiogenesis. PLoS One. 7:e334182012. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Lu H, Dalgard CL, Mohyeldin A, McFate T,
Tait AS and Verma A: Reversible inactivation of HIF-1 prolyl
hydroxylases allows cell metabolism to control basal HIF-1. J Biol
Chem. 280:41928–41939. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Hirschhaeuser F, Sattler UG and
Mueller-Klieser W: Lactate: A metabolic key player in cancer.
Cancer Res. 71:6921–6925. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Végran F, Boidot R, Michiels C, Sonveaux P
and Feron O: Lactate influx through the endothelial cell
monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway
that drives tumor angiogenesis. Cancer Res. 71:2550–2560. 2011.
View Article : Google Scholar
|
|
129
|
Lee DC, Sohn HA, Park ZY, Oh S, Kang YK,
Lee KM, Kang M, Jang YJ, Yang SJ, Hong YK, et al: A lactate-induced
response to hypoxia. Cell. 161:595–609. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Zhang J, Dong C, Wu L, Chen L, Zhang L and
Shi L: Diagnostic value of a lactylation-related gene signature in
hepatocellular carcinoma. Transl Cancer Res. 14:296–312. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Luan S: The role of histone lactylation
genes in hepatocellular carcinoma prognostic models and their
immune cell infiltration features: A comprehensive analysis of
single-cell, spatial transcriptome, Mendelian randomization and
experiment. Discov Oncol. 16:292025. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Zhang Q, Cao L and Xu K: Role and
mechanism of lactylation in cancer. Zhongguo Fei Ai Za Zhi.
27:471–479. 2024.In Chinese. PubMed/NCBI
|
|
133
|
Asmamaw MD, He A, Zhang LR, Liu HM and Gao
Y: Histone deacetylase complexes: Structure, regulation and
function. Biochim Biophys Acta Rev Cancer. 1879:1891502024.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Abeywardana MY, Whedon SD, Lee K, Nam E,
Dovarganes R, DuBois-Coyne S, Haque IA, Wang ZA and Cole PA:
Multifaceted regulation of sirtuin 2 (Sirt2) deacetylase activity.
J Biol Chem. 300:1077222024. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Byun JK: Tumor lactic acid: A potential
target for cancer therapy. Arch Pharm Res. 46:90–110. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Zhao Y, Li M, Luo Z, Su M and Yu C: Recent
progress in the therapeutic modulation of lactate for cancer
treatment. Adv Ther. 6:22002542023. View Article : Google Scholar
|
|
137
|
Halford S, Veal GJ, Wedge SR, Payne GS,
Bacon CM, Sloan P, Dragoni I, Heinzmann K, Potter S, Salisbury BM,
et al: A Phase I dose-escalation study of AZD3965, an oral
monocarboxylate transporter 1 inhibitor, in patients with advanced
cancer. Clin Cancer Res. 29:1429–1439. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Benyahia Z, Blackman MCNM, Hamelin L,
Zampieri LX, Capeloa T, Bedin ML, Vazeille T, Schakman O and
Sonveaux P: In vitro and in vivo characterization of MCT1 inhibitor
AZD3965 confirms preclinical safety compatible with breast cancer
treatment. Cancers (Basel). 13:5692021. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Beloueche-Babari M, Casals Galobart T,
Delgado-Goni T, Wantuch S, Parkes HG, Tandy D, Harker JA and Leach
MO: Monocarboxylate transporter 1 blockade with AZD3965 inhibits
lipid biosynthesis and increases tumour immune cell infiltration.
Br J Cancer. 122:895–903. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Xiang F, Zhang Z, Li Y, Xia B, Liao Y,
Yang C, He Z, Lin L and Xie J: Honokiol targeting SIRT3: From
molecular mechanisms to therapeutic opportunities. FASEB J.
39:e707982025. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Gu XY, Yang JL, Lai R, Zhou ZJ, Tang D, Hu
L and Zhao LJ: Impact of lactate on immune cell function in the
tumor microenvironment: mechanisms and therapeutic perspectives.
Front Immunol. 16:15633032025. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Papadaki S and Magklara A: Regulation of
metabolic plasticity in cancer stem cells and implications in
cancer therapy. Cancers (Basel). 14:59122022. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Zang Y, Wang A, Zhang J, Xia M, Jiang Z,
Jia B, Lu C, Chen C, Wang S, Zhang Y, et al: Hypoxia promotes
histone H3K9 lactylation to enhance LAMC2 transcription in
esophageal squamous cell carcinoma. iScience. 27:1101882024.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Zhao Y, Jiang J, Zhou P, Deng K, Liu Z,
Yang M, Yang X, Li J, Li R and Xia J: H3K18 lactylation-mediated
VCAM1 expression promotes gastric cancer progression and metastasis
via AKT-mTOR-CXCL1 axis. Biochem Pharmacol. 222:1161202024.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Wang F, Chen L, Kong D, Zhang X, Xia S,
Liang B, Li Y, Zhou Y, Zhang Z, Shao J, et al: Canonical Wnt
signaling promotes HSC glycolysis and liver fibrosis through an
LDH-A/HIF-1α transcriptional complex. Hepatology. 79:606–623. 2024.
View Article : Google Scholar :
|
|
146
|
Heuser C, Renner K, Kreutz M and Gattinoni
L: Targeting lactate metabolism for cancer immunotherapy-a matter
of precision. Semin Cancer Biol. 88:32–45. 2023. View Article : Google Scholar
|
|
147
|
Li S, Lu X and Zhang L: Lactylation: the
malignant playbook of hepatocellular carcinoma cells and their
roadmap to therapy resistance. Front Immunol. 16:17524042026.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Billiard J, Dennison JB, Briand J, Annan
RS, Chai D, Colón M, Dodson CS, Gilbert SA, Greshock J, Jing J, et
al: Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and
reverse aerobic glycolysis in cancer cells. Cancer Metab. 1:192013.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Fiume L, Vettraino M, Manerba M and Di
Stefano G: Inhibition of lactic dehydrogenase as a way to increase
the anti-proliferative effect of multi-targeted kinase inhibitors.
Pharmacol Res. 63:328–334. 2011. View Article : Google Scholar
|
